• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Oracle (ORCL) Expands Ontario Health Rollout, Is The Stock Cheap Now?

    Simply Wall St·07/29/2026 07:13:41
    Listen to the news

    Oracle (ORCL) is back in focus after Baycrest Hospital agreed to join Sunnybrook Health Sciences Centre’s Oracle Health electronic health record rollout in Ontario, extending the company’s footprint in Canadian digital health infrastructure.

    See our latest analysis for Oracle.

    For context, Oracle’s share price has fallen sharply over the past year, with a 30 day share price return down 19.24% and a year to date share price return down 38.71%, while the 1 year total shareholder return is down 51.47% but the 5 year total shareholder return remains positive at 43%. Recent contract wins in U.S. defense software, cloud distribution and now Canadian healthcare have arrived alongside concerns about heavy AI infrastructure spending and debt. This helps explain why sentiment has weakened even as Oracle continues to secure large, long duration relationships like the Ontario health record rollout.

    If you are weighing Oracle’s recent pullback against other AI opportunities, this is also a useful moment to scan the market for alternative cloud and AI platforms through our screener for 56 AI infrastructure stocks

    Bulls see Oracle’s AI backlog and long contracts as mispriced after the selloff. Bears focus on debt, free cash flow strain and OpenAI exposure. Which side does today’s valuation actually support?

    Most Popular Narrative: 38% Undervalued

    According to andre_santos, the most followed narrative on Oracle pegs fair value at $192.59 per share versus the last close of $119.96, which implies a wide valuation gap based on detailed cash flow and multiple based work.

    To calculate the intrinsic value of the company I will use multiple methods.

    Discounted Cash Flows (DCF) intrinsic value is estimated by projecting its free cash flows over the next 10 years and discounting them to present value using the estimated cost of capital.

    Read the complete narrative.

    Curious what gets Oracle to that higher fair value range. The narrative leans heavily on faster growth in revenue and earnings and assumes robust margins over time, then cross checks this with several market based valuation anchors.

    Result: Fair Value of $192.59 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Oracle’s high estimated 12% cost of capital and very high uncertainty rating could pressure valuations if cash generation or AI related spending disappoints expectations.

    Find out about the key risks to this Oracle narrative.

    Next Steps

    With sentiment on Oracle clearly split, this is a good time to move quickly, review the data for yourself, and weigh both the concerns and the potential rewards. To help frame that view, start with our summary of 4 key rewards and 3 important warning signs

    Looking for more Oracle investment ideas beyond this pullback

    Do not stop with Oracle. Use this moment to broaden your watchlist, compare different types of opportunities, and pressure test your thinking before the next big move.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.